DBV to resubmit BLA for peanut allergy therapy 3Q19

DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT) said on Feb. 13 it plans to resubmit a BLA for its peanut allergy therapy Viaskin Peanut in 3Q19.

DBV said it withdrew the original BLA on Dec. 19 after FDA said the application lacked details regarding manufacturing procedures and quality control (see "DBV Withdraws BLA for Peanut Allergy Therapy")...